Drug Information Association Logo
Corporate Tagline

Session 3 Tract 2 - Communications: Social Media


Day & Time:
October 29, 1:30PM - 3:00PM


Session 3 Tract 2 - Communications: Social Media

Deirdre Cozier
Manager, Regulatory Operations, Policy & Intelligence
sanofi-aventis Canada Inc., Canada

The increasing popularity of social media networks is changing consumer behavior. An entire generation now communicates via tweets, pins and IMs. Consumer endorsement has a powerful, and near instantaneous, effect on company strategy. This has required the business community to adapt to this technology and engage their customers in more personal and virtual ways. In an industry as tightly regulated as pharmaceuticals, the use of social media platforms to engage, inform and promote raises some unique challenges. This session will explore the uses of social media both from an industry and regulator perspective. From R&D, to internal collaboration and compliance considerations, the three speakers will share best practices and provide valuable tips to ensure that your use of social media platforms is successful.

Presentation(s) & Speaker(s):
Harnessing Power of SMAC (Social Media, Mobility, Analytics & Cloud) to Drive Transformation in Clinical R&D
Susant Mallick, MBA
Head, Clinical Standards and Analytics Center of Excellence in Life Sciences
Cognizant Technology Solutions Corporation, India

Social Media as Health Communication Tools in Canada
Brenda M Gryfe, MPharm
Director, Canadian Regulatory Affairs
OptumInsight (Canada) Inc., Canada

Regulatory Considerations of Using Social Media
Alain G. Musende, PhD
Head, Regulatory Advertising Unit
Health Canada, Canada

© 2014